Recombinant human hyaluronidase PH20 (rHuPH20) facilitates subcutaneous infusions of large volumes of immunoglobulin in a swine model

Drug Delivery and Translational Research

Volumn 2, Issue 4, 2012, Pages 254-264

  Kang, David W ^a   Jadin, Laurence ^a   Nekoroski, Tara ^a   Drake, Fred H ^a   Zepeda, Monica L ^a  

^a Halozyme Therapeutics Inc   (United States)

Author keywords

Immunoglobulin; Induration; Miniature swine; Primary immunodeficiency disease; Recombinant human hyaluronidase; Subcutaneous infusion

Indexed keywords

IMMUNOGLOBULIN; IMMUNOGLOBULIN G; RECOMBINANT HYALURONIDASE;

ABDOMEN; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG INDICATION; FEMALE; HOME CARE; HOSPITAL CARE; IMMUNE DEFICIENCY; INJECTION SITE INDURATION; INJECTION SITE SWELLING; LASER DOPPLER FLOWMETRY; MINIPIG; NONHUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; TISSUE INJURY;

EID: 84866161074     PISSN: 2190393X     EISSN: 21903948     Source Type: Journal    
DOI: 10.1007/s13346-012-0065-3     Document Type: Article

References (35)

1. Rezaei N, Hedayat M, Aghamohammadi A, Nichols KE. Primary immunodeficiency diseases associated with increased susceptibility to viral infections and malignancies. J Allergy Clin Immunol. 2011; 127(6): 1329-41.
2. Moise A, Nedelcu FD, Toader MA, Sora SM, Tica A, Ferastraoaru DE, Constantinescu I. Primary immunodeficiencies of the B lymphocyte. J Med Life. 2010; 3(1): 60-3.
3. Gardulf A. Immunoglobulin treatment for primary antibody deficiencies. BioDrugs. 2007; 21: 105-16.
4. Kittner JM, Grimbacher B, Wulff W, Jäger B, Schmidt RE. Patients' attitude to subcutaneous immunoglobulin substitution as home therapy. J Clin Immunol. 2006; 26(4): 400-5.
5. Gardulf A, Nicolay U. Replacement Ig therapy and self-therapy at home improve the health-related quality of life in patients with primary antibody deficiencies. Curr Opin Allergy Clin Immunol. 2006; 6(6): 434-42.
6. Misbah S, Sturzenegger MH, Borte M, Shapiro RS, Wasserman RL, Berger M, Ochs HD. Subcutaneous immunoglobulin: opportunities and outlook. Clin Exp Immunol. 2009; 158 Suppl 1: 51-9.
7. Gustafson R, Gardulf A, Hansen S, Leibl H, Engl W, Lindén M, Müller A, Hammarstrm L. Rapid subcutaneous immunoglobulin administration every second week results in high and stable serum immunoglobulin G levels in patients with primary antibody deficiencies. Clin Exp Immunol. 2008; 152: 274-9.
8. Ochs HD, Gupta S, Kiessling P, Nicolay U, Berger M, Subcutaneous Ig Study Group. Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J Clin Immunol. 2006; 26(3): 265-73.
9. Borte M, Bernatowska E, Ochs HD, Roifman CM, Vivaglobin Study Group. Efficacy and safety of home-based subcutaneous immunoglobulin replacement therapy in paediatric patients with primary immunodeficiencies. Clin Exp Immunol. 2011; 164(3): 357-64.
10. Gardulf A, Nicolay U, Math D, Asensio O, Bernatowska E, Böck A, Costa-Carvalho BT, Granert C, Haag S, Hernández D, Kiessling P, Kus J, Matamoros N, Niehues T, Schmidt S, Schulze I, Borte M. Children and adults with primary antibody deficiencies gain quality of life by subcutaneous Ig self-infusions at home. J Allergy Clin Immunol. 2004; 114(4): 936-42.
11. Nicolay U, Kiessling P, Berger M, Gupta S, Yel L, Roifman CM, Gardulf A, Eichmann F, Haag S, Massion C, Ochs HD. Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous Ig self-infusions at home. J Clin Immunol. 2006; 26(1): 65-72.
12. Hizentra Package Insert. Available at http://www. fda. gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM203150. pdf.
13. Bookbinder LH, Hofer A, Haller MF, Zepeda ML, Keller GA, Lim JE, Edgington TS, Shepard HM, Patton JS, Frost GI. A recombinant human enzyme for enhanced interstitial transport of therapeutics. J Contr Release. 2006; 114(2): 230-41.
14. Frost GI. Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration. Exp Opin Drug Deliv. 2007; 4: 427-40.
15. NCT00814320 at ClinicalTrials. gov. Gammagard Liquid and rHuPH20 in PID. Available at http://www. clinicaltrials. gov/ct2/show/NCT00814320?term=NCT00814320& rank=1.
16. Melamed I, Wasserman RL, Stein M, Rubinstein A, McCoy B, Engl W, Leibl H, Gelmont D, Grossman WJ, Schiff RI, and the IGSC, 10 % rHuPH20 Study Group. Tolerability of human immunoglobulin 10 % (Ig) administered subcutaneously (SC) or facilitated with recombinant human hyaluronidase (rHuPH20) in patients with primary immunodeficiency disease (PIDD). Presented at the Annual Meeting of the Clinical Immunology Society, May 19-22, 2011. Abstract #28.
17. Wasserman RL, Melamed I, Stein M, Rubinstein A, McCoy B, Engl W, Leibl H, Gelmont D, Grossman WJ, Schiff RI, and the IGSC, 10 % rHuPH20 Study Group. Pharmacokinetics (PK) of human immunoglobulin 10 % (Ig) administered intravenously (IV), subcutaneously (SC) or facilitated with recombinant human hyaluronidase (rHuPH20) in patients with primary immunodeficiency disease (PIDD). Presented at the Annual Meeting of the Clinical Immunology Society, May 19-22, 2011. Abstract #53.
18. Svendsen O. The minipig in toxicology. Exp Toxicol Pathol. 2006; 57: 335-9.
19. van der Laan JW, Brightwell J, McAnulty P, Ratky J, Stark C, Steering Group of the RETHINK Project. Regulatory acceptability of the minipig in the development of pharmaceuticals, chemicals and other products. J Pharm Toxicol Methods. 2010; 62(3): 184-95.
20. Mahl JA, Vogel BE, Court M, Kolopp M, Roman D, Nogués V. The minipig in dermatotoxicology: methods and challenges. Exp Toxicol Pathol. 2006; 57(5-6): 341-5.
21. Nunoya T, Shibuya K, Saitoh T, Yazawa H, Nakamura K, Baba Y, Hirai T. Use of miniature pig for biomedical research, with reference to toxicologic studies. J Tox Pathol. 2007; 20: 125-32.
22. Golla S, Madihally S, Robinson Jr RL, Gasem KA. Quantitative structure-property relationship modeling of skin sensitization: a quantitative prediction. Toxicol Vitro. 2009; 23(3): 454-65.
23. Porter CJ, Edwards GA, Charman SA. Lymphatic transport of proteins after s. c. injection: implications of animal model selection. Adv Drug Deliv Rev. 2001; 50(1-2): 157-71.
24. Supersaxo A, Hein WR, Steffen H. Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration. Pharm Res. 1990; 7(2): 167-9.
25. Berger M. Subcutaneous immunoglobulin replacement in primary immunodeficiencies. Clin Immunol. 2004; 112: 1-7.
26. Berger M. Subcutaneous administration of IgG. Immunol Allergy Clin North Am. 2008; 285(4): 779-802.
27. Chouksey A, Duff K, Wasserbauer N, Berger M. Subcutaneous immunoglobulin-g replacement therapy with preparations currently available in the United States for intravenous or intramuscular use: reasons and regimens. Allergy Asthma Clin Immunol. 2005; 1(3): 120-30.
28. Singh S. Acute compartment syndrome. Curr Orthop. 2004; 18: 468-76.
29. Steinberg BD. Evaluation of limb compartments with increased interstitial pressure. An improved noninvasive method for determining quantitative hardness. J Biomech. 2005; 38(8): 1629-35.
30. Mars M, Hadley GP. Raised intracompartmental pressure and compartment syndrome. Injury. 1998; 29(6): 403-11.
31. Kalns J, Cox J, Baskin J, Santos A, Odland R, Recura Jr S. Threshold model for extremity compartment syndrome in swine. J Surg Res. 2011; 167(1): 13-9.
32. Leu AJ, Leu HJ, Franzeck UK, Bollinger A. Microvascular changes in chronic venous insufficiency-a review. Cardiovasc Surg. 1995; 3(3): 237-45.
33. Laferrière A, Millecamps M, Xanthos DN, Xiao WH, Siau C, de Mos M, Sachot C, Ragavendran JV, Huygen FJ, Bennett GJ, Coderre TJ. Cutaneous tactile allodynia associated with microvascular dysfunction in muscle. Mol Pain. 2008; 4: 49.
34. Uhlmann D, Armann B, Gaebel G, Ludwig S, Hess J, Pietsch UC, Escher E, Fieldler M, Tannapfel A, Hauss J, Witzigmann H. Endothelin A receptor blockade reduces hepatic ischemia/reperfusion injury after warm ischemia in a pig model. J Gastrointest Surg. 2003; 7(3): 331-9.
35. Reddy NP, Cochran GV. Interstitial fluid flow as a factor in decubitus ulcer formation. J Biomech. 1981; 14(12): 879-81.